Using methoxy polyethylene glycol-epoetin beta injection may increase the risk that blood clots will form in or move to the legs and lungs. (medlineplus.gov)
Before having any surgery, even dental surgery, tell your doctor or dentist that you are being treated with methoxy polyethylene glycol-epoetin beta injection, especially if you are having coronary artery bypass graft (CABG) surgery or surgery to treat a bone problem. (medlineplus.gov)
Your doctor will adjust your dose of methoxy polyethylene glycol-epoetin beta injection so that your hemoglobin level (amount of a protein found in red blood cells) is just high enough that you do not need a red blood cell transfusion (transfer of one person's red blood cells to another person's body to treat severe anemia). (medlineplus.gov)
If you receive enough methoxy polyethylene glycol-epoetin beta injection to increase your hemoglobin to a normal or near normal level, there is a greater risk that you will have a stroke or develop serious or life-threatening heart problems including heart attack, and heart failure. (medlineplus.gov)
Your doctor will monitor your blood pressure often during your treatment with methoxy polyethylene glycol-epoetin beta injection. (medlineplus.gov)
Your doctor will also order certain tests to check your body's response to methoxy polyethylene glycol-epoetin beta injection. (medlineplus.gov)
Your doctor may decrease your dose or tell you to stop using methoxy polyethylene glycol-epoetin beta injection for a period of time if the tests show that you are at high risk of experiencing serious side effects. (medlineplus.gov)
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with methoxy polyethylene glycol-epoetin beta injection and each time you refill your prescription. (medlineplus.gov)
Talk to your doctor about the risks of receiving methoxy polyethylene glycol-epoetin beta injection. (medlineplus.gov)
Methoxy polyethylene glycol-epoetin beta injection should not be used to treat anemia caused by cancer chemotherapy. (medlineplus.gov)
Methoxy polyethylene glycol-epoetin beta injection is used to treat anemia (a lower than normal number of red blood cells) in people with chronic kidney failure (condition in which the kidneys slowly and permanently stop working over a period of time) in adults on and not on dialysis and in children 5 years of age and older on dialysis who have already received another treatment for anemia. (medlineplus.gov)
Methoxy polyethylene glycol-epoetin beta injection should not be used to treat anemia caused by cancer chemotherapy and should not be used in place of a red blood cell transfusion to treat severe anemia. (medlineplus.gov)
The Washington Manual , www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/109352/all/methoxy_polyethylene_glycol_epoetin_beta. (unboundmedicine.com)
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. (wikipedia.org)
In several studies reported between 1990 and 2001, recombinant human erythropoietin (r-HuEPO, epoetin alfa) increased haemoglobin (Hb) levels and subsequently ameliorated anaemia in cancer patients. (nature.com)
The trial included 356 adults with endogenous serum erythropoietin (sEPO) levels under 500 U/L who were randomized 1:1 to receive luspatercept (1.0-1.75 mg/kg) every 3 weeks or epoetin alfa (450-1050 IU/kg) weekly for at least 24 weeks and stratified by baseline red blood cell (RBC) transfusion burden, baseline sEPO, and ring sideroblast (RS) status. (rarediseaseadvisor.com)
In patients receiving long-term dialysis, recombinant erythropoietin (eg, epoetin alfa or darbepoetin alfa ) along with iron supplements is the treatment of choice. (msdmanuals.com)
Procrit4
The product is a proposed biosimilar to Amgen/Johnson & Johnson's Epogen/Eprex/Procrit (epoetin alfa), which had worldwide sales of US$3 billion in 2015 [3]. (gabionline.net)
The FDA rejected, for a second time, Pfizer's application for approval of its biosimilar epoetin alfa (Epoetin Hospira), a colony-stimulating factor indicated for anemia, biosimilar to Epogen and Procrit. (centerforbiosimilars.com)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Procrit (Epoetin Alfa) where reactions include fatigue. (druglib.com)
Examples include epoetin alpha (Epogen, Procrit) and darbepoetin alfa (Aranesp). (healthline.com)
Eprex3
Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta), and two biosimilar products, Binocrit (epoetin alfa) and Retacrit (epoetin zeta), were compared using (1) high performance size exclusion chromatography, (2) ELISA, (3) SDS-PAGE, (4) capillary zone electrophoresis and (5) in-vivo potency. (springer.com)
Fass environmental information for Eprex (epoetin alfa) from Janssen (downloaded 2019-07-09). (janusinfo.se)
The epoetin alfa biosimilar, Retacrit (epoetin alfa-epbx), is produced by US pharma giant Pfizer. (gabionline.net)
Epogen4
Epoetin is manufactured and marketed by Amgen under the brand name Epogen. (wikipedia.org)
Epogen (epoetin alfa) is a man-made form of a protein that helps your body produce red blood cells used to treat anemia (a lack of red blood cells in the body). (rxlist.com)
Our Epogen (epoetin alfa) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations. (rxlist.com)
Injection3
Epoetin is quite effective, but it has a 2-week delay between the injection and when your red blood cell count really starts to come back. (epnet.com)
Both filgrastim and epoetin are given by injection in your doctor's office. (epnet.com)
About half the patients experienced the injection of epoetin-a as moderately to extremely painful. (wren-clothing.com)
Biosimilar epoetin alfa1
Sandoz has become the first company to develop and receive European Commission approval for its biosimilar epoetin alfa, achieving another important milestone in its efforts to bring high quality, cost-effective biological medicines to patients. (worldpharmanews.com)
Bone marrow to make1
Epoetin helps your bone marrow to make new red blood cells. (epnet.com)
Recombinant1
Epoetin alfa is a 165- amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology . (rxlist.com)
Dose5
We did a secondary analysis of patients with chronic kidney disease enrolled in the Correction of Hemoglobin in the Outcomes in Renal Insufficiency trial to measure the potential for competing benefit and harm from achieved hemoglobin and epoetin dose trials. (nih.gov)
In the 4 month analysis, significantly more patients in the high-hemoglobin compared to the low-hemoglobin arm were unable to achieve target hemoglobin and required high-dose epoetin-alpha. (nih.gov)
In unadjusted analyses, the inability to achieve a target hemoglobin and high-dose epoetin-alpha were each significantly associated with increased risk of a primary endpoint (death, myocardial infarction, congestive heart failure or stroke). (nih.gov)
In adjusted models, high-dose epoetin-alpha was associated with a significant increased hazard of a primary endpoint but the risk associated with randomization to the high hemoglobin arm did not suggest a possible mediating effect of higher target via dose. (nih.gov)
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (patientbloodmanagement.org)
Erythropoiesis-stimu1
Luspatercept versus epoetin alfa (EA) for treatment of anemia in patients with erythropoiesis-stimulating agent (ESA)-naïve lower-risk myelodysplastic syndromes (LR-MDS) requiring red blood cell (RBC) transfusions: data from the phase III COMMANDS study. (rarediseaseadvisor.com)
Hospira1
The company received a recommendation for approval from FDA's Oncologic Drugs Advisory Committee (ODAC) for Epoetin Hospira on 25 May 2017 [1]. (gabionline.net)
Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-platinum-based chemotherapy. (nature.com)
These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life. (nature.com)
Effects of epoetin beta on left ventricular mass in patients with chronic kidney disease: Echocardiographic results from the CREATE study. (hdcn.com)
In conclusion, epoetin beta treatment prevented further progression of LVH in CKD patients with mild-to- moderate anemia. (hdcn.com)
and is recommending patients to change to other epoetins. (gabionline.net)
Treatment-emergent adverse events were reported in 92.1% of patients in the luspatercept group and 85.2% of those in the epoetin alfa group. (rarediseaseadvisor.com)
Progression to higher-risk MDS occurred in 2.8% of luspatercept-treated patients vs 4% of epoetin alfa-treated patients. (rarediseaseadvisor.com)
Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. (wustl.edu)
Epoetin-beta is used to treat patients with metastatic cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life. (wustl.edu)
In contrast, for epoetin-P, most of the patients described the administration as painless or, in a minority of cases, as only minimally painful. (wren-clothing.com)
Progression3
On-treatment progression to acute myeloid leukemia (AML) was observed in 0.6% of each group, and overall AML progression rates were 2.2% with luspatercept and 2.8% with epoetin alfa. (rarediseaseadvisor.com)
This meta-analysis of 12 randomised, controlled studies evaluated the impact of epoetin-beta on overall survival, tumour progression and thromboembolic events (TEEs). (wustl.edu)
The results of this meta-analysis indicate that when used within current EORTC treatment guidelines, epoetin-beta has no negative impact on survival, tumour progression or TEEs-related mortality. (wustl.edu)
Anaemia2
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. (ox.ac.uk)
OBJECTIVES: To assess the effectiveness and cost-effectiveness of epoetin alpha, epoetin beta and darbepoetin alpha (referred to collectively in this report as epo) in anaemia associated with cancer, especially that attributable to cancer treatment. (ox.ac.uk)
20231
In the phase 3 COMMANDS trial ( NCT03682536 ), luspatercept-aamt demonstrated superiority against epoetin alfa in the treatment of anemia in adults with erythropoiesis‑stimulating agents (ESA)-naïve transfusion-dependent lower‑risk myelodysplastic syndromes (LR‑MDS), according to interim efficacy and safety results reported at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) . (rarediseaseadvisor.com)
Cancer1
Epoetin may also be used to prevent or treat anemia that is caused by surgery or medicines (eg, zidovudine) that are used for other conditions, such as HIV or cancer. (wren-clothing.com)
Conclusion1
Conclusion: Epoetin alfa has low potential for bioaccumulation. (janusinfo.se)
Efficacy1
Treatment discontinuation occurred in 44% of the luspatercept group vs 60% of the epoetin alfa group, most commonly for lack of efficacy (15.7% vs 32.4%, respectively). (rarediseaseadvisor.com)
Sufficient1
Risk of environmental impact of Epoetin alfa cannot be excluded, since there is not sufficient ecotoxicity data available. (janusinfo.se)
Treatment2
The Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin beta (CREATE) study included assessment of anemia treatment with epoetin beta on LVH. (hdcn.com)
The median duration of treatment was 41.6 weeks in the luspatercept arm and 27 weeks in the epoetin alfa arm. (rarediseaseadvisor.com)
Clinical1
According to Pfizer, the issues noted in the Warning Letter do not relate specifically to the manufacture of epoetin alfa, and no additional clinical data was requested in the CRL at this time to support a future approval. (centerforbiosimilars.com)
Drug1
The US Food and Drug Administration (FDA) approved its first epoetin alfa biosimilar on 15 May 2018. (gabionline.net)
Approval1
FDA advisors recommend approval of Pfizer's epoetin alfa biosimilar [www.gabionline.net]. (gabionline.net)
Risk1
The use of epoetin alfa in this indication must be balanced against the reported risk of thrombo-embolic events. (medscape.co.uk)